Symbols / PSNL $7.12 +4.86%
PSNL Chart
About
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 744.98M |
| Enterprise Value | 549.04M | Income | -81.27M | Sales | 69.65M |
| Book/sh | 2.55 | Cash/sh | 2.29 | Dividend Yield | — |
| Payout | 0.00% | Employees | 259 | IPO | — |
| P/E | — | Forward P/E | -7.63 | PEG | — |
| P/S | 10.70 | P/B | 2.79 | P/C | — |
| EV/EBITDA | -7.04 | EV/Sales | 7.88 | Quick Ratio | 6.46 |
| Current Ratio | 6.76 | Debt/Eq | 16.85 | LT Debt/Eq | — |
| EPS (ttm) | -0.91 | EPS next Y | -0.93 | EPS Growth | — |
| Revenue Growth | 3.20% | Earnings | 2026-05-05 | ROA | -18.21% |
| ROE | -35.02% | ROIC | — | Gross Margin | 22.65% |
| Oper. Margin | -145.67% | Profit Margin | -116.69% | Shs Outstand | 104.63M |
| Shs Float | 68.12M | Short Float | 14.49% | Short Ratio | 8.87 |
| Short Interest | — | 52W High | 11.50 | 52W Low | 2.83 |
| Beta | 2.11 | Avg Volume | 1.42M | Volume | 733.22K |
| Target Price | $11.43 | Recom | Strong_buy | Prev Close | $6.79 |
| Price | $7.12 | Change | 4.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.43
Mean price target
2. Current target
$7.12
Latest analyst target
3. DCF / Fair value
$-7.39
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.12
Low
$10.00
High
$13.00
Mean
$11.43
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-05 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $10 |
| 2026-02-27 | main | Needham | Buy → Buy | $12 |
| 2026-02-11 | main | BTIG | Buy → Buy | $13 |
| 2026-01-26 | main | Guggenheim | Buy → Buy | $13 |
| 2026-01-09 | reit | BTIG | Buy → Buy | $12 |
| 2025-12-02 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $11 |
| 2025-11-11 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $9 |
| 2025-11-11 | main | Guggenheim | Buy → Buy | $12 |
| 2025-11-11 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-11-11 | main | BTIG | Buy → Buy | $12 |
| 2025-11-06 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-11-05 | main | Needham | Buy → Buy | $10 |
| 2025-10-22 | main | BTIG | Buy → Buy | $11 |
| 2025-09-08 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-08-06 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-05-07 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-04-10 | reit | Needham | Buy → Buy | $7 |
| 2025-03-17 | init | Craig-Hallum | — → Buy | $8 |
| 2025-02-28 | main | Needham | Buy → Buy | $7 |
| 2025-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
- Personalis taps MRD lead Richard Chen as president to advance cancer detection - Stock Titan ue, 17 Mar 2026 20
- $PSNL stock is down 16% today. Here's what we see in our data. - Quiver Quantitative hu, 12 Mar 2026 19
- Personalis (PSNL) grants options and RSUs to Chief Legal Officer - Stock Titan ue, 17 Mar 2026 20
- Personalis (NASDAQ:PSNL) Stock Price Down 8.1% - What's Next? - MarketBeat hu, 12 Mar 2026 17
- Personalis (PSNL) Appoints Richard Chen as President - GuruFocus Wed, 18 Mar 2026 00
- Personalis Stock Pre-Market (-5.3%): FY26 Guidance Overshadows Q4 EPS Beat - Trefis Fri, 06 Mar 2026 11
- Personalis appoints Richard Chen as president and updates compensation package - Investing.com ue, 17 Mar 2026 23
- How A New Price Target Is Shaping The Evolving Story For Personalis (PSNL) - Yahoo Finance Wed, 21 Jan 2026 08
- Personalis (PSNL) CFO granted 206,250 options and 34,375 RSUs - Stock Titan ue, 17 Mar 2026 20
- $PSNL stock is up 13% today. Here's what we see in our data. - Quiver Quantitative hu, 22 Jan 2026 08
- Personalis (NASDAQ:PSNL) Trading 6.6% Higher - Time to Buy? - MarketBeat Fri, 13 Mar 2026 16
- Personalis (PSNL) CEO receives major stock option and RSU grants - Stock Titan ue, 17 Mar 2026 20
- Personalis Stock Pre-Market (-4.0%): Downgrade Cites Competitive Headwinds - Trefis ue, 13 Jan 2026 08
- Personalis (PSNL) awards RSUs and stock options to its CMO - Stock Titan ue, 17 Mar 2026 20
- Personalis (NASDAQ: PSNL) elevates Richard Chen to President - Stock Titan ue, 17 Mar 2026 20
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1201 | 13812 | — | Sale at price 11.50 per share. | TACHIBANA AARON | Chief Operating Officer | — | 2026-01-22 00:00:00 | D |
| 1 | 1201 | 11001 | — | Conversion of Exercise of derivative security at price 9.16 per share. | TACHIBANA AARON | Chief Operating Officer | — | 2026-01-22 00:00:00 | D |
| 2 | 320267 | 2739181 | — | Purchase at price 7.67 - 11.00 per share. | TEMPUS AI INC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-22 00:00:00 | D |
| 3 | 103668 | 1117541 | — | Sale at price 10.78 per share. | TACHIBANA AARON | Chief Operating Officer | — | 2025-11-25 00:00:00 | D |
| 4 | 103668 | 949599 | — | Conversion of Exercise of derivative security at price 9.16 per share. | TACHIBANA AARON | Chief Operating Officer | — | 2025-11-25 00:00:00 | D |
| 5 | 29612 | 266212 | — | Sale at price 8.99 per share. | HALL CHRISTOPHER M. | Chief Executive Officer | — | 2025-11-03 00:00:00 | D |
| 6 | 452 | 2970 | — | Sale at price 6.57 per share. | CHEN RICHARD | Officer | — | 2025-07-28 00:00:00 | D |
| 7 | 641 | 4211 | — | Sale at price 6.57 per share. | TACHIBANA AARON | Chief Operating Officer | — | 2025-07-28 00:00:00 | D |
| 8 | 910 | 4504 | — | Sale at price 4.95 per share. | CHEN RICHARD | Officer | — | 2025-05-16 00:00:00 | D |
| 9 | 1675 | 8291 | — | Sale at price 4.95 per share. | MOORE STEPHEN MICHAEL | Officer | — | 2025-05-16 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.00 | 0.21 |
| NormalizedEBITDA | -71.00M | -70.30M | -83.17M | -104.64M |
| TotalUnusualItems | 0.00 | -13.64M | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -13.64M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -81.27M | -81.28M | -108.30M | -113.31M |
| ReconciledDepreciation | 10.05M | 10.94M | 11.30M | 8.43M |
| ReconciledCostOfRevenue | 53.87M | 57.79M | 55.27M | 51.70M |
| EBITDA | -71.00M | -70.30M | -96.81M | -104.64M |
| EBIT | -81.04M | -81.24M | -108.10M | -113.07M |
| NetInterestIncome | 6.95M | 5.49M | 5.79M | 2.19M |
| InterestExpense | 205.00K | 24.00K | 110.00K | 201.00K |
| InterestIncome | 7.16M | 5.51M | 5.90M | 2.40M |
| NormalizedIncome | -81.27M | -81.28M | -94.65M | -113.31M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -81.27M | -81.28M | -108.30M | -113.31M |
| TotalExpenses | 157.71M | 152.88M | 169.78M | 180.58M |
| TotalOperatingIncomeAsReported | -88.06M | -68.27M | -109.94M | -115.53M |
| DilutedAverageShares | 59.25M | 48.18M | 45.70M | 43.89M |
| BasicAverageShares | 59.25M | 48.18M | 45.70M | 43.89M |
| DilutedEPS | -1.37 | -2.25 | -2.48 | -1.49 |
| BasicEPS | -1.37 | -2.25 | -2.48 | -1.49 |
| DilutedNIAvailtoComStockholders | -81.27M | -81.28M | -108.30M | -113.31M |
| NetIncomeCommonStockholders | -81.27M | -81.28M | -108.30M | -113.31M |
| NetIncome | -81.27M | -81.28M | -108.30M | -113.31M |
| NetIncomeIncludingNoncontrollingInterests | -81.27M | -81.28M | -108.30M | -113.31M |
| NetIncomeContinuousOperations | -81.27M | -81.28M | -108.30M | -113.31M |
| TaxProvision | 21.00K | 18.00K | 83.00K | 40.00K |
| PretaxIncome | -81.25M | -81.27M | -108.21M | -113.28M |
| OtherIncomeExpense | -142.00K | -18.48M | -17.71M | 61.00K |
| OtherNonOperatingIncomeExpenses | -142.00K | -18.48M | -4.07M | 61.00K |
| SpecialIncomeCharges | 0.00 | -13.64M | 0.00 | 0.00 |
| ImpairmentOfCapitalAssets | 0.00 | 5.57M | 0.00 | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | 8.08M | 0.00 | 0.00 |
| NetNonOperatingInterestIncomeExpense | 6.95M | 5.49M | 5.79M | 2.19M |
| InterestExpenseNonOperating | 205.00K | 24.00K | 110.00K | 201.00K |
| InterestIncomeNonOperating | 7.16M | 5.51M | 5.90M | 2.40M |
| OperatingIncome | -88.06M | -68.27M | -96.29M | -115.53M |
| OperatingExpense | 103.83M | 95.09M | 114.50M | 128.88M |
| ResearchAndDevelopment | 50.26M | 48.91M | 64.78M | 64.91M |
| SellingGeneralAndAdministration | 53.57M | 46.19M | 49.73M | 63.97M |
| GrossProfit | 15.78M | 26.82M | 18.21M | 13.35M |
| CostOfRevenue | 53.87M | 57.79M | 55.27M | 51.70M |
| TotalRevenue | 69.65M | 84.61M | 73.48M | 65.05M |
| OperatingRevenue | 68.33M | 84.49M | 73.08M | 64.64M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 102.48M | 85.17M | 50.48M | 46.71M |
| ShareIssued | 102.48M | 85.17M | 50.48M | 46.71M |
| TotalDebt | 39.95M | 44.25M | 47.73M | 48.65M |
| TangibleBookValue | 261.19M | 202.96M | 129.44M | 218.14M |
| InvestedCapital | 262.38M | 204.63M | 131.09M | 220.36M |
| WorkingCapital | 228.32M | 171.89M | 99.51M | 166.57M |
| NetTangibleAssets | 261.19M | 202.96M | 129.44M | 218.14M |
| CapitalLeaseObligations | 38.76M | 42.58M | 46.08M | 46.43M |
| CommonStockEquity | 261.19M | 202.96M | 129.44M | 218.14M |
| TotalCapitalization | 261.19M | 202.96M | 129.44M | 218.14M |
| TotalEquityGrossMinorityInterest | 261.19M | 202.96M | 129.44M | 218.14M |
| StockholdersEquity | 261.19M | 202.96M | 129.44M | 218.14M |
| GainsLossesNotAffectingRetainedEarnings | 104.00K | -23.00K | -222.00K | -912.00K |
| OtherEquityAdjustments | 104.00K | -23.00K | -222.00K | -912.00K |
| RetainedEarnings | -631.26M | -549.99M | -468.71M | -360.41M |
| AdditionalPaidInCapital | 892.33M | 752.96M | 598.36M | 579.46M |
| CapitalStock | 10.00K | 9.00K | 5.00K | 5.00K |
| CommonStock | 10.00K | 9.00K | 5.00K | 5.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 72.98M | 67.31M | 95.66M | 74.56M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 33.35M | 36.19M | 48.42M | 41.43M |
| OtherNonCurrentLiabilities | 1.48M | 1.30M | 5.16M | 389.00K |
| DerivativeProductLiabilities | 0.00 | 4.94M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 31.87M | 34.88M | 38.32M | 41.04M |
| LongTermCapitalLeaseObligation | 31.87M | 34.88M | 38.32M | 41.04M |
| CurrentLiabilities | 39.63M | 31.13M | 47.23M | 33.13M |
| OtherCurrentLiabilities | 5.46M | 2.02M | 6.49M | |
| CurrentDeferredLiabilities | 1.56M | 3.10M | 3.29M | 1.29M |
| CurrentDeferredRevenue | 1.56M | 3.10M | 3.29M | 1.29M |
| CurrentDebtAndCapitalLeaseObligation | 8.08M | 9.37M | 9.41M | 7.61M |
| CurrentCapitalLeaseObligation | 6.89M | 7.70M | 7.76M | 5.39M |
| CurrentDebt | 1.19M | 1.67M | 1.65M | 2.22M |
| OtherCurrentBorrowings | 1.19M | 1.67M | 1.65M | 2.22M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.34M | 8.85M | 13.13M | 9.55M |
| PayablesAndAccruedExpenses | 17.19M | 7.80M | 14.92M | 14.68M |
| CurrentAccruedExpenses | 4.20M | 1.40M | 0.00 | 1.70M |
| Payables | 12.99M | 6.40M | 14.92M | 12.98M |
| TotalTaxPayable | 37.00K | 123.00K | 121.00K | |
| AccountsPayable | 12.99M | 6.40M | 14.92M | 12.85M |
| TotalAssets | 334.16M | 270.27M | 225.10M | 292.70M |
| TotalNonCurrentAssets | 66.21M | 67.25M | 78.36M | 93.00M |
| OtherNonCurrentAssets | 6.28M | 2.53M | 3.14M | 4.59M |
| NetPPE | 59.93M | 64.73M | 75.22M | 88.42M |
| AccumulatedDepreciation | -53.91M | -46.04M | -37.67M | -26.93M |
| GrossPPE | 113.84M | 110.77M | 112.89M | 115.34M |
| Leases | 41.69M | 41.56M | 40.81M | 40.37M |
| ConstructionInProgress | 56.00K | 899.00K | 3.48M | 3.99M |
| OtherProperties | 15.12M | 16.45M | 17.85M | 26.48M |
| MachineryFurnitureEquipment | 56.98M | 51.86M | 50.74M | 44.50M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 267.95M | 203.01M | 146.74M | 199.70M |
| OtherCurrentAssets | 5.65M | 3.93M | 4.36M | 6.81M |
| CurrentDeferredAssets | 887.00K | 1.96M | 4.81M | 2.21M |
| PrepaidAssets | 7.09M | |||
| Inventory | 5.26M | 3.98M | 5.66M | 6.38M |
| RawMaterials | 5.26M | 3.98M | 5.66M | 6.38M |
| Receivables | 16.20M | 8.14M | 17.73M | 16.64M |
| AccountsReceivable | 16.20M | 8.14M | 17.73M | 16.64M |
| CashCashEquivalentsAndShortTermInvestments | 239.95M | 185.01M | 114.18M | 167.66M |
| OtherShortTermInvestments | 115.71M | 93.59M | 57.20M | 78.53M |
| CashAndCashEquivalents | 124.25M | 91.42M | 56.98M | 89.13M |
| CashEquivalents | 119.33M | 90.26M | 53.34M | 83.51M |
| CashFinancial | 4.92M | 1.15M | 3.65M | 5.62M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -79.45M | -46.75M | -67.17M | -120.13M |
| RepaymentOfDebt | -2.00M | -1.13M | -3.26M | -2.29M |
| IssuanceOfDebt | 2.59M | 0.00 | 3.44M | 1.19M |
| IssuanceOfCapitalStock | 126.80M | 97.82M | 3.51M | 0.00 |
| CapitalExpenditure | -4.50M | -1.60M | -10.91M | -49.90M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | |
| IncomeTaxPaidSupplementalData | 23.00K | 38.00K | 64.00K | 47.00K |
| EndCashPosition | 126.03M | 93.20M | 58.77M | 90.92M |
| BeginningCashPosition | 93.20M | 58.77M | 90.92M | 107.38M |
| EffectOfExchangeRateChanges | 6.00K | -22.00K | -16.00K | -127.00K |
| ChangesInCash | 32.82M | 34.45M | -32.13M | -16.33M |
| FinancingCashFlow | 130.34M | 114.67M | 11.03M | 1.37M |
| CashFlowFromContinuingFinancingActivities | 130.34M | 114.67M | 11.03M | 1.37M |
| NetOtherFinancingCharges | -189.00K | -1.23M | -342.00K | |
| ProceedsFromStockOptionExercised | 3.15M | 19.21M | 7.34M | 2.46M |
| NetCommonStockIssuance | 126.80M | 97.82M | 3.51M | 0.00 |
| CommonStockIssuance | 126.80M | 97.82M | 3.51M | 0.00 |
| NetIssuancePaymentsOfDebt | 585.00K | -1.13M | 174.00K | -1.10M |
| NetLongTermDebtIssuance | 585.00K | -1.13M | 174.00K | -1.10M |
| LongTermDebtPayments | -2.00M | -1.13M | -3.26M | -2.29M |
| LongTermDebtIssuance | 2.59M | 0.00 | 3.44M | 1.19M |
| InvestingCashFlow | -22.57M | -35.07M | 13.10M | 52.54M |
| CashFlowFromContinuingInvestingActivities | -22.57M | -35.07M | 13.10M | 52.54M |
| NetInvestmentPurchaseAndSale | -18.06M | -33.71M | 24.01M | 102.43M |
| SaleOfInvestment | 192.11M | 88.00M | 127.95M | 223.92M |
| PurchaseOfInvestment | -210.17M | -121.71M | -103.94M | -121.49M |
| NetPPEPurchaseAndSale | -4.50M | -1.36M | -10.91M | -49.90M |
| SaleOfPPE | 0.00 | 242.00K | 0.00 | |
| PurchaseOfPPE | -4.50M | -1.60M | -10.91M | -49.90M |
| OperatingCashFlow | -74.95M | -45.15M | -56.26M | -70.23M |
| CashFlowFromContinuingOperatingActivities | -74.95M | -45.15M | -56.26M | -70.23M |
| ChangeInWorkingCapital | -10.19M | -2.59M | 13.48M | 10.61M |
| ChangeInOtherWorkingCapital | -1.54M | -4.12M | 5.95M | -2.72M |
| ChangeInOtherCurrentLiabilities | -5.02M | -2.31M | 884.00K | 12.39M |
| ChangeInPayablesAndAccruedExpense | 6.86M | -11.32M | 5.92M | 1.61M |
| ChangeInAccruedExpense | 2.31M | -2.40M | 742.00K | -1.48M |
| ChangeInPayable | 4.55M | -8.92M | 5.18M | 3.09M |
| ChangeInAccountPayable | 4.55M | -8.92M | 5.18M | 3.09M |
| ChangeInPrepaidAssets | -2.22M | 1.14M | 3.75M | 484.00K |
| ChangeInInventory | -204.00K | 4.42M | -1.93M | -2.98M |
| ChangeInReceivables | -8.06M | 9.59M | -1.09M | 1.82M |
| ChangesInAccountReceivables | -8.06M | 9.59M | -1.09M | 1.82M |
| OtherNonCashItems | 1.03M | 1.49M | 5.62M | 4.55M |
| StockBasedCompensation | 9.43M | 10.69M | 14.05M | 19.43M |
| AssetImpairmentCharge | 0.00 | 5.57M | 0.00 | 0.00 |
| AmortizationOfSecurities | -3.99M | -2.67M | -2.00M | 57.00K |
| DepreciationAmortizationDepletion | 10.05M | 10.94M | 11.30M | 8.43M |
| DepreciationAndAmortization | 10.05M | 10.94M | 11.30M | 8.43M |
| OperatingGainsLosses | 18.27M | 4.03M | ||
| GainLossOnInvestmentSecurities | 18.27M | 4.03M | ||
| NetIncomeFromContinuingOperations | -81.27M | -81.28M | -108.30M | -113.31M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PSNL
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|